Betulinic acid prevents liver fibrosis by binding Lck and suppressing Lck in HSC activation and proliferation. (5th October 2022)

• Record Type: Journal Article
• Authors: Zhao, Huizi; Wu, Lin; Zhang, Yuan; Feng, Shiqi; Ding, Yuhao; Deng, Xin; Feng, Rui; Li, Jun; Ma, Taotao; Huang, Cheng
• Is Part Of: Journal of ethnopharmacology. Volume 296(2022)
• Publication Date: 2022-10-05
• Subjects: Lck -- SOCS1 -- Hepatic stellate cell -- Liver fibrosis -- Betulinic acid; α-SMA α-smooth muscle actin -- BA Betulinic acid -- COl1α1 Type I collagen -- HSC Hepatic stellate cells -- JAK Janus kinase -- Lck Lymphocyte-specific protein tyrosine kinase -- SOCS1 Suppressor of cytokine signaling 1 -- STAT1 signal transducer and activator of transcription 1; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2022.115459
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Hypericum japonicum Thunb. ex Murray ( Hypericaceae ), named 'Tianjihuang' is a traditional Chinese medicine with hepatoprotective, antibacterial, and antitumour effects. Betulinic acid (BA) is its active constituent and has been found to have a number of biological effects, including antiviral, anti-inflammatory, and anti-malarial therapeutic properties. Non-alcoholic fatty liver disease and acute alcoholic liver injury have both been proven to benefit from BA. BA's effects and mechanism on liver fibrosis are still unknown. Aim of the study : The purpose of this study was to explore the influence of BA on lymphocyte-specific protein tyrosine kinase (Lck), a non-receptor Src family kinase, that reduces liver fibrosis by inhibiting the phosphorylation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways through the interaction of Lck and SOCS1. Materials and methods: A liver fibrosis model was established in vivo with CCl4 using haematoxylin and eosin (HE) staining, Masson staining, immunohistochemical staining, and immunofluorescence staining. Hepatic stellate cells were induced with transforming growth factor (TGF)-β1 in vitro, using Western blotting, immunofluorescence staining, and a cell scratch assay. Results: In a CCl4 -induced mouse hepatic fibrosis model and in TGF-β1-activated HSC-T6 cells, BA markedly reduced fibrosis, as demonstrated by the dramatic downregulation of α-smooth muscle actin (α-SMA) and type I collagen alpha-1 (Col1α1) protein levels in vivo and in vitro . BA significantly suppressed the activity and expression of Lck in vitro . Overexpression of Lck may diminish the effect of BA on liver fibrosis. In vitro, BA also greatly increased the expression of suppressor of cytokine signalling 1 (SOCS1) while it considerably inhibited the expression of p-JAK and p-STAT1. Conclusions: These findings suggest that BA promotes the expression of SOCS1 by the inhibiting the interaction between Lck and SOCS1, followed by the inhibition of JAK/STAT phosphorylation to prevent the progression of liver fibrosis. Therefore, BA could be used as a promising natural supplement for the treatment of liver fibrosis. Graphical abstract: Image 1